StreetInsider.com News Articles

Damora Therapeutics moves incorporation from Delaware to Cayman Islands

Fri, 17 Jul 2026 08:01:26 -0400

Damora Therapeutics, Inc. (NASDAQ: DMRA) completed its redomestication from the State of Delaware to the Cayman Islands, effective July 16, 2026, according to a press release from the company.

As part of the redomestication, each outstanding share of the Delaware company's common stock automatically converted into one ordinary share, with a par value of $0.00001 per share, of the Cayman Islands entity. Each outstanding share of any series of preferred stock also automatically converted into one share of the corresponding series of preferred shares of the new entity.

The redomestication was approved by the company's board of directors and later approved by

Damora Announces Redomestication from Delaware to Cayman Islands

Fri, 17 Jul 2026 08:00:00 -0400

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the completion of the redomestication of the Company from the State of Delaware to the Cayman Islands, effective on July 16, 2026. Each outstanding share of the Delaware Company’s common stock automatically converted into one ordinary share, par value $0.00001 per share, of the Company, and each outstanding share of any series of the Delaware Company’s preferred stock automatically converted into one outstanding share of the corresponding

Damora Announces Redomestication from Delaware to Cayman Islands

Fri, 17 Jul 2026 08:00:00 -0400

Damora Announces Redomestication from Delaware to Cayman Islands

Fri, 17 Jul 2026 08:00:00 -0400

Damora Announces Redomestication from Delaware to Cayman Islands

Fri, 17 Jul 2026 08:00:00 -0400

Form 4 Damora Therapeutics, For: Jul 03 Filed by: Winslow Garrett

Tue, 07 Jul 2026 20:01:00 -0400

si-local-file:///var/storage/secattach/20260707/26743084.html

Form 4 Damora Therapeutics, For: Jul 03 Filed by: Winslow Garrett

Tue, 07 Jul 2026 20:01:00 -0400

si-local-file:///var/storage/secattach/20260707/26743084.html

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 01 Jul 2026 16:01:00 -0400

BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to nine newly-hired, non-executive employees on July 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 453,500 shares of Damora’s common

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 01 Jul 2026 16:01:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 453,500 shares of Damora’s common

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 01 Jul 2026 16:01:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 453,500 shares of Damora’s common

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 01 Jul 2026 16:01:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 453,500 shares of Damora’s common

Form 144 Damora Therapeutics, Filed by: Firmani Lori

Mon, 22 Jun 2026 14:27:00 -0400

si-local-file:///var/storage/secattach/20260622/26672369.html

Form 144 Damora Therapeutics, Filed by: Firmani Lori

Mon, 22 Jun 2026 14:27:00 -0400

si-local-file:///var/storage/secattach/20260622/26672369.html

Form 8-K Damora Therapeutics, For: Apr 28

Wed, 17 Jun 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260617/26659698.html

Form 8-K Damora Therapeutics, For: Apr 28

Wed, 17 Jun 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260617/26659698.html

H.C. Wainwright Starts Damora Therapeutics (DMRA) at Buy

Thu, 11 Jun 2026 06:35:10 -0400

(Updated - June 11, 2026 6:35 AM EDT)

H.C. Wainwright analyst Mitchell Kapoor initiates coverage on Damora Therapeutics (NASDAQ: DMRA) with a Buy rating and a price target of $45.00.

The analyst comments "DMRA offers value opportunity to own the biotech theme that keeps hitting—validated MOAs with next-gen iterations. After the theme has seen multiple successful runs across I&I, Damora brings the concept to hematology. We have seen the capital markets reward similar stories: Oruka (ORKA; Buy) is now a $3.5B+ market cap after appreciation on its half-life extended Skyrizi/IL-23 concept in psoriasis; Generate Bio (GENB; Buy) is >$1.5B market cap with

H.C. Wainwright Starts Damora Therapeutics (DMRA) at Buy

Thu, 11 Jun 2026 06:35:10 -0400

(Updated - June 11, 2026 6:35 AM EDT)

H.C. Wainwright analyst Mitchell Kapoor initiates coverage on Damora Therapeutics (NASDAQ: DMRA) with a Buy rating and a price target of $45.00.

TD Cowen Starts Damora Therapeutics (DMRA) at Buy

Mon, 08 Jun 2026 05:32:16 -0400

TD Cowen analyst Marc Frahm initiates coverage on Damora Therapeutics (NASDAQ: DMRA) with a Buy rating.

The analyst comments "DMRA is developing best-in-class molecules for validated targets in MPN disease. Lead asset DMR-001 is a mCALR targeted mAb for the treatment of ET and MF demonstrating 3-10x potency in vitro relative to the most advanced competitor molecule, with convenient SC dosing. 001's preclinical profile addresses the high unmet need for a disease-modifying therapy in mCALR-driven MPNs. Initiating at Buy."

For an analyst ratings summary and ratings history on Damora Therapeutics click here. For more ratings news on Damora Therapeutics click

TD Cowen Starts Damora Therapeutics (DMRA) at Buy

Mon, 08 Jun 2026 05:32:16 -0400

TD Cowen analyst Marc Frahm initiates coverage on Damora Therapeutics (NASDAQ: DMRA) with a Buy rating.

For an analyst ratings summary and ratings history on Damora Therapeutics click here. For more ratings news on Damora Therapeutics click

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 08:00:00 -0400

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on June 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 372,000 shares of Damora’s common

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 08:00:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 372,000 shares of Damora’s common

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 08:00:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 372,000 shares of Damora’s common

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 08:00:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 372,000 shares of Damora’s common

Wedbush Starts Damora Therapeutics (DMRA) at Outperform

Thu, 28 May 2026 06:53:54 -0400

Wedbush analyst David Nierengarten initiates coverage on Damora Therapeutics (NASDAQ: DMRA) with a Outperform rating and a price target of $35.00.

For an analyst ratings summary and ratings history on Damora Therapeutics click here. For more ratings news on Damora Therapeutics click here.

Shares of Damora Therapeutics closed at $25.21 yesterday.

Form SCHEDULE 13G/A Damora Therapeutics, Filed by: Point72 Asset Management, L.P.

Fri, 15 May 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260515/26506235.html